PDF(Pubmed)
Abstract：
Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, leading to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo-induced cardiotoxicity is of paramount importance to treating and/or preventing it. This review aims to illustrate several mechanisms thought to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic strategies to prevent Doxo-induced cardiotoxicity.
摘要：
心脏毒性是几种化疗药物的主要副作用。阿霉素（Doxo）是最常用的蒽环类药物之一，用于治疗许多肿瘤，但是急性和慢性心脏毒性的发展限制了其临床应用。不同的研究只关注长期Doxo给药的效果，但是最近的数据表明，心肌细胞损伤是Doxo在单次给药后诱导的早期事件，随后会出现进行性功能下降，导致明显的心力衰竭.了解Doxo诱导的心脏毒性的早期阶段涉及的分子机制对于治疗和/或预防它至关重要。这篇综述旨在说明被认为是Doxo诱导的心脏毒性的几种机制，如氧化和亚硝化应激，炎症,和线粒体功能障碍。此外，在这里,我们报告了来自体外和体内研究的数据,这些数据表明了预防Doxo诱导的心脏毒性的新治疗策略.
